Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

American Family Physician September 15, 2005 Rindfleisch & Muller	Diagnosis and Management of Rheumatoid Arthritis Rheumatoid arthritis is the most common inflammatory arthritis, affecting 0.8 percent of the adult population worldwide. It is a lifelong disease, although patients can go into remission. Physicians must be aware of common comorbidities.
Nursing February 2010 Daniel A. Hussar	New Drugs 2010, PART 1 In this article, you'll learn about 16 new drugs.
American Family Physician November 1, 2001 Ric Anthony Koler	Dermatomyositis Dermatomyositis is an idiopathic inflammatory myopathy with characteristic skin manifestations. Although the disorder is rare, early recognition and treatment are important ways to decrease the morbidity of systemic complications...
Nursing June 2010 Daniel A. Hussar	New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs.
American Family Physician November 1, 2001 Thomas R. Riley	Preventive Strategies in Chronic Liver Disease Chronic liver disease is the 10th leading cause of death in the United States. Preventive care can significantly reduce the progression of liver disease. Part I: Alcohol, Vaccines, Toxic Medications and Supplements, Diet and Exercise...
Nursing June 2011 Daniel A. Hussar	New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis.
Nursing July 2011 Susan Simmons	Recognizing and Managing Rheumatoid Arthritis Here's what rheumatoid arthritis is, how it's diagnosed and treated, and what you can do to help patients manage the disease.
Nursing January 2011 Carl A. Kirton	HIV: The Changing Epidemic Since its emergence in the early 1980s, HIV infection in the United States has evolved from an acute debilitating condition to a chronic, treatable illness.
Nurse Practitioner February 2011 Jennifer M. Belavic	Annual Drug Update: 2010 in Review In 2010, the FDA approved several new drugs and new indications for use in primary care. From new therapies for adults with rheumatoid arthritis to a combination drug for benign prostatic hyperplasia, NPs need to be aware of the latest medications now available.
American Family Physician October 1, 2000	Taking the immunoinhibitor methotrexate What is methotrexate?... How do I take methotrexate?... What else should I remember about taking methotrexate?... I am a man and I want to get my partner pregnant. Can I take methotrexate?...
Nursing February 2009 Daniel A. Hussar	New Drugs 09: Part 1 Learn about 10 new drugs, including nebivolol HCl, the newest beta-adrenergic blocking agent for hypertension.
Nurse Practitioner February 2012 Jennifer M. Belavic	Annual drug update 2011 in review Many new medications were approved throughout 2011. This article will cover a variety of drugs that will be useful in nurse practitioner practice
Nursing November 2011 Jeanne Held-Warmkessel	Taming Three High-Risk Chemotherapy Complications A review of three common chemotherapy-associated complications that can be serious enough to require hospitalization: febrile neutropenia, chemotherapy-related nephrotoxicity, and chemotherapy-related enterotoxicity.
American Family Physician July 15, 2004 Wu & Schiff	Sarcoidosis This systemic granulomatous disease of unknown cause predominately affects young and middle-aged adults. Diagnosis is based on clinicoradiologic findings plus histologic evidence of noncaseating epithelioid granulomas, and exclusion of other granulomatous diseases.
Nursing March 2012 Daniel A. Hussar	New Drugs 2012: part I In this article, you'll learn about 11 recently approved drugs.
Nurse Practitioner July 2010 Kristine A. Scordo	Treating antiretroviral-induced dyslipidemia in HIV-infected adults Studies indicate that HIV-infected patients (both males and females) may be at an increased risk for the development of cardiovascular disease
American Family Physician March 15, 2005 Paul T. Giboney	Mildly Elevated Liver Transaminase Levels in the Asymptomatic Patient Mild elevations in liver chemistry tests can reveal serious underlying conditions or have transient and benign etiologies. If elevations persist after an appropriate period of observation, further testing may include ultrasonography and other serum studies.
Nursing March 2009 Mary G. McKinley	Recognizing and Responding to Acute Liver Failure By quickly recognizing the signs and symptoms of acute liver failure, you can help your patient improve his odds of surviving this often-deadly condition.
American Family Physician September 1, 2006 Heidelbaugh & Bruderly	Cirrhosis and Chronic Liver Failure: Part I. Diagnosis and Evaluation Part I of a two-part on how to diagnose and determine treatment for cirrhosis and chronic liver failure.
American Family Physician June 1, 2006 Bayard, Holt & Boroughs	Nonalcoholic Fatty Liver Disease Nonalcoholic fatty liver disease is a common condition associated with metabolic syndrome. It is the most common cause of elevated liver enzymes in U.S. adults, and is diagnosed after ruling out other causes of steatosis, particularly infectious hepatitis and alcohol abuse.
American Family Physician November 1, 2005 Lozeau & Potter	Diagnosis and Management of Ectopic Pregnancy If a woman of reproductive age presents with abdominal pain, vaginal bleeding, syncope, or hypotension, the physician should perform a pregnancy test. If the patient is pregnant, the physician should perform a work-up to detect possible ectopic or ruptured ectopic pregnancy.
American Family Physician July 15, 2006 Junnila & Cartwright	Chronic Musculoskeletal Pain in Children: Part II. Rheumatic Causes Primary care physicians should have a working knowledge of rheumatic diseases of childhood that manifest primarily as musculoskeletal pain. Children with juvenile rheumatoid arthritis can present with painless joint inflammation and may have normal results on rheumatologic tests.
The Motley Fool October 8, 2010 Brian Orelli	Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size.
American Family Physician February 15, 2006 Luba & Stulberg	Chronic Plaque Psoriasis Patients and physicians should understand that psoriasis is a chronic disease without a cure, and that it is important to have realistic expectations of treatment. Treatment should focus on improvement, not disappearance, of lesions.
The Motley Fool April 29, 2011 Brian Orelli	Nice Efficacy, Pfizer, But... Safety data is most important at this point. Nothing can stop Pfizer's oral rheumatoid arthritis treatment tofacitinib.
The Motley Fool July 9, 2009 Brian Orelli	Yes! It Can Handle the Pressure Rigel Pharmaceuticals' latest tests show that the side effects from its rheumatoid arthritis drug candidate R788 are manageable.
Nurse Practitioner July 2008 Lynn A. Kelso	Cirrhosis: Caring for Patients with End-stage Liver Failure Caring for patients with end-stage liver disease can be very challenging for NPs.
Chemistry World September 11, 2013 Emma Stoye	Call to overhaul liver toxicity testing Outdated assays for monitoring liver health could have caused dozens of drug candidates to be wrongly scrapped during development, according to new research.
The Motley Fool April 13, 2011 Brian Orelli	Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients.
Managed Care November 2005 Vogenberg, Liebeskind & Ritter	Addressing the Hidden Costs of Rheumatoid Arthritis Health plans can work directly with customers to design rheumatoid arthritis management plans that address indirect but substantial costs.
The Motley Fool July 14, 2011 Brian Orelli	Good Data, but Lots of Competition Regeneron's sarilumab passes a phase 2b trial.
The Motley Fool August 10, 2010 Ryan McBride	Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive.
The Motley Fool March 4, 2011 Brian Orelli	Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors.
American Family Physician June 15, 2004 Kataria, & Brent	Spondyloarthropathies Identification, features and strength of recommendations of this diverse group of inflammatory arthritides.
The Motley Fool December 15, 2010 Brian Orelli	Beautiful Efficacy, Wrong Pill Lexicon Pharmaceuticals presented beautiful data showing a pill it gave rheumatoid arthritis patients decreased symptoms in 49% of patients. Unfortunately, the pill was a dummy pill with no active ingredient.
American Family Physician September 15, 2003 Richie & Francis	Diagnostic Approach to Polyarticular Joint Pain Polyarticular joint pain (i.e., pain in more than four joints) poses a diagnostic challenge because of the extensive differential diagnosis. Consequently, family physicians need to keep the diagnosis open in evaluating patients who present with pain in multiple joints.
American Family Physician January 15, 2001 Scott C. Conley	Deep Waters A physician can actually achieve significant therapeutic benefit for a patient by addressing the manifestations of an illness that no stethoscope or laboratory test can detect. Simply put, there is healing power in words.
Chemistry World June 13, 2007 James Mitchell Crow	Renewed Therapeutic Promise for Arthritis Patients Three new treatments for rheumatoid arthritis, the most common chronic inflammatory joint disease in the industrialized world, offer hope to patients where existing drugs have failed.
The Motley Fool August 26, 2009 Brian Orelli	Small Change, Big Impact? A small difference in wording could have a huge effect on sales of Bristol-Myers Squibb's Orencia.
HHMI Bulletin Fall 2012 Sarah C. P. Williams	The Fat You Can't See Without the liver acting as a filter and energy producer, a person can't survive, and no artificial organ can perform all of its duties. But in one in three Americans -- and similar numbers in other developed nations -- the liver has lost its luster.
The Motley Fool March 9, 2010 Brian Orelli	The Opportunity That Wasn't Roche and Biogen Idec are suspending development of ocrelizumab for rheumatoid arthritis because patients are coming down with opportunistic infections.
The Motley Fool December 11, 2009 Brian Orelli	Roche and Biogen's Blockbuster Making Good Progress Roche and Biogen move their potential blockbuster through the clinical trial maze.
The Motley Fool September 28, 2010 Brian Orelli	Don't Get Stuck! Invest in Needle-Free Drugs Here's how to make some money off society's general disdain for needles through next-generation drugs.
The Motley Fool June 26, 2009 Brian Orelli	The $16 Billion Market That Could Make You Rich A large market just waiting to be taken over.
The Motley Fool September 6, 2011 Brian Orelli	Better Late Than Never? Maybe. Can Vertex's rheumatoid arthritis drug, VX-509, succeed this late in the game?
The Motley Fool November 8, 2010 Brian Orelli	No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective.
American Family Physician September 15, 2005	Rheumatoid Arthritis: What You Should Know A patient hand out on the condition, its diagnosis and treatment options.
Pharmaceutical Executive September 1, 2012 Al Topin	Doctors' Words No Longer Gospel In the digital age, physicians don't call the shots when it comes to healthcare guidance. Marketers must appeal to multiple sources in seeking ways to garner patient adherence and loyalty.
Managed Care October 2004 Thomas Morrow	Evaluating New Therapies for Psoriasis Along with traditional systemic therapies, the American Academy of Dermatology recommends four biologic agents as first-line treatment for psoriasis patients who are candidates for systemic therapy.
Managed Care February 2006 Thomas Morrow	New Rheumatoid Arthritis Treatment Has Potential to Reduce Payer's Costs B-cells and their markers, once overlooked in the pathophysiology of rheumatoid arthritis, may hold the key for a new treatment regimen.